CAR-T Meeting 2023 | Strategies to minimize the occurrence of CRS and ICANS in patients treated with CAR-T therapy
In this video, Eleni Gavriilaki, MD, PhD, G. Papanikolaou Hospital, Thessaloniki, Greece, comments on the importance of improving strategies to minimize the occurrence of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in patients treated with CAR-T therapy. Dr Gavriilaki highlights the role of tocilizumab and dexamethasone, and also discusses novel agents being explored in this space. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
This is a very interesting issue. So we are really interested not only in the clinical part, but also in the translational research on how to minimize CRS and ICANS. So that’s why we use in our everyday practice, the bedside [inaudible] and the close collaboration with neurologists and ICU doctors. And we believe that this strategy has led us to zero ICU hospitalizations, the first two indications, and this strategy has helped us throughout the most severe patients...
This is a very interesting issue. So we are really interested not only in the clinical part, but also in the translational research on how to minimize CRS and ICANS. So that’s why we use in our everyday practice, the bedside [inaudible] and the close collaboration with neurologists and ICU doctors. And we believe that this strategy has led us to zero ICU hospitalizations, the first two indications, and this strategy has helped us throughout the most severe patients. We all know that tocilizumab and dexamethasone are needed early in the process, we do not need to be afraid of them. And we also now know that we have more drugs against interleukins like anakinra or siltuximab that we can use in the high-risk patients. And my personal view is that we need to know more about this and gather these experiences because if you try to look at guidelines and recommendations, you will see only two rows of thinking and sentences about them. And maybe we need to emphasize more of that because we want to save all our patients.
Read more...
Disclosures
EG has received research funding and honoraria from Gilead.
